Elan Corporation, plc – Product Pipeline Review – 2013

Date: April 30, 2013
Pages: 94
Price:
US$ 1,500.00 US$ 1,350.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E6E7D5B3AD5EN
Leaflet:

Download PDF Leaflet

Elan Corporation, plc – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Elan Corporation, plc - Product Pipeline Review - 2013” provides data on the Elan Corporation, plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Elan Corporation, plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Elan Corporation, plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Elan Corporation, plc - Brief Elan Corporation, plc overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Elan Corporation, plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Elan Corporation, plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Elan Corporation, plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Elan Corporation, plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Elan Corporation, plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Elan Corporation, plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Elan Corporation, plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Elan Corporation, plc and identify potential opportunities in those areas.
Elan Corporation, plc Snapshot
Elan Corporation, plc Overview
Key Information
Key Facts
Elan Corporation, plc – Research and Development Overview
Key Therapeutic Areas
Elan Corporation, plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Elan Corporation, plc – Pipeline Products Glance
Elan Corporation, plc – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Elan Corporation, plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Elan Corporation, plc – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Elan Corporation, plc – Drug Profiles
Autoimmune Research
Product Description
Mechanism of Action
R&D Progress
Beta Secretase Research
Product Description
Mechanism of Action
R&D Progress
ELND-005
Product Description
Mechanism of Action
R&D Progress
ELND-005+ [lamotrigine]+ [valproic acid]
Product Description
Mechanism of Action
R&D Progress
Gamma Secretase Research
Product Description
Mechanism of Action
R&D Progress
natalizumab
Product Description
Mechanism of Action
R&D Progress
natalizumab SC
Product Description
Mechanism of Action
R&D Progress
Onclave Research Program
Product Description
Mechanism of Action
R&D Progress
Parkinson's Research
Product Description
Mechanism of Action
R&D Progress
Elan Corporation, plc – Pipeline Analysis
Elan Corporation, plc – Pipeline Products by Therapeutic Class
Elan Corporation, plc – Pipeline Products by Route of Administration
Elan Corporation, plc – Pipeline Products By Mechanism of Action
Elan Corporation, plc – Recent Pipeline Updates
Elan Corporation, plc - Dormant Projects
Elan Corporation, plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ELND-002
ELND-006
ELND-007
Elan Corporation, plc – Company Statement
Elan Corporation, plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Elan Corporation, plc - Key Manufacturing Facilities
Elan Corporation, plc, Recent Developments
Elan Corporation, plc- Press Release
Mar 18, 2013: Biogen Idec and Elan Announce New Tysabri Data Reaffirms Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status
Mar 08, 2013: Elan Provides Update On Tysabri Transaction
Jan 15, 2013: Biogen Idec And Elan Submit Applications For First-Line Use Of Tysabri In Anti-JCV Antibody Negative Patients With Multiple Sclerosis
Dec 22, 2010: Biogen And Elan Submit Applications To Update TYSABRI Labeling
Aug 09, 2010: Elan And Transition Announce Topline Results From Phase II Study Of ELND005 For Alzheimer's Disease
Apr 16, 2010: Patient-Reported Outcomes Study Shows Improvements In Quality of Life Among Patients After One Year Of Treatment With Tysarbi
Apr 13, 2010: Biogen Idec, Elan Present Data On TYSABRI At Annual Meeting Of American Academy Of Neurology
Mar 25, 2010: Biogen Idec and Elan Enroll First Patient In Head-to-Head Study Of MS Treatments
Financial Deals Landscape
Elan Corporation, plc, Deals Summary
Elan Corporation, plc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
University of Cambridge Enters Into Joint Venture Agreement With Elan
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan
Elan Enters Into Collaboration With Pharma Product Development
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Elan Corporation Amends Its Collaboration With Transition Therapeutics
PharmatrophiX Enters Into Co-Development Agreement With Elan
Circ Pharma Enters Into Co-Development Agreement With Elan
Graffinity Pharma Enters Into Research Agreement With Elan
Azur Pharma Enters Into Co-Development Agreement With Elan
Licensing Agreements
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan
Ariadne Enters Into Licensing Agreement With Elan Pharma
Zogenix Enters Into Licensing Agreement With Elan
GeneGo Enters Into Licensing Agreement With Elan Pharma
Amarin Enters Into Licensing Agreement With Elan
Nitromed Enters Into Licensing Agreement With Elan Pharma
Equity Offering
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million
Elan Completes Private Placement Of $885 Million
Debt Offering
Elan Completes Public Offering Of Notes Due 2019 For $600 Million
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million
Asset Transactions
Biogen Idec Completes Acquisition Of Tysabri From Elan
Azur Pharma Acquires PRIALT From Elan Pharma
Johnson & Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Elan Corporation, plc, Key Information
Elan Corporation, plc, Key Facts
Elan Corporation, plc – Pipeline by Indication, 2013
Elan Corporation, plc – Pipeline by Stage of Development, 2013
Elan Corporation, plc – Monotherapy Products in Pipeline, 2013
Elan Corporation, plc – Combination Treatment Modalities in Pipeline, 2013
Elan Corporation, plc – Phase III, 2013
Elan Corporation, plc – Phase II, 2013
Elan Corporation, plc – Phase I, 2013
Elan Corporation, plc – Pre-Clinical, 2013
Elan Corporation, plc – Discovery, 2013
Elan Corporation, plc – Pipeline By Therapeutic Class, 2013
Elan Corporation, plc – Pipeline By Route of Administration, 2013
Elan Corporation, plc – Pipeline Products By Mechanism of Action, 2013
Elan Corporation, plc – Recent Pipeline Updates, 2013
Elan Corporation, plc - Dormant Developmental Projects,2013
Elan Corporation, plc - Discontinued Pipeline Products, 2013
Elan Corporation, plc, Subsidiaries
Elan Corporation, plc, Key Manufacturing Facilities
Elan Corporation, plc, Deals Summary
University of Cambridge Enters Into Joint Venture Agreement With Elan
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan
Elan Enters Into Collaboration With Pharma Product Development
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Elan Corporation Amends Its Collaboration With Transition Therapeutics
PharmatrophiX Enters Into Co-Development Agreement With Elan
Circ Pharma Enters Into Co-Development Agreement With Elan
Graffinity Pharma Enters Into Research Agreement With Elan
Azur Pharma Enters Into Co-Development Agreement With Elan
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan
Ariadne Enters Into Licensing Agreement With Elan Pharma
Zogenix Enters Into Licensing Agreement With Elan
GeneGo Enters Into Licensing Agreement With Elan Pharma
Amarin Enters Into Licensing Agreement With Elan
Nitromed Enters Into Licensing Agreement With Elan Pharma
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million
Elan Completes Private Placement Of $885 Million
Elan Completes Public Offering Of Notes Due 2019 For $600 Million
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million
Biogen Idec Completes Acquisition Of Tysabri From Elan
Azur Pharma Acquires PRIALT From Elan Pharma
Johnson & Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan

LIST OF FIGURES

Elan Corporation, plc – Pipeline by Indication, 2013
Elan Corporation, plc – Pipeline by Stage of Development, 2013
Elan Corporation, plc – Monotherapy Products in Pipeline, 2013
Elan Corporation, plc – Combination Treatment Modalities in Pipeline, 2013
Elan Corporation, plc – Pipeline By Route of Administration, 2013
Elan Corporation, plc - Pipeline Products By Mechanism of Action, 2013

Ask Your Question

Elan Corporation, plc – Product Pipeline Review – 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: